News Detail

This Evommune Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Benzinga · 03/18 12:00

Listen to the news

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Truist Securities analyst Danielle Brill initiated coverage on Maze Therapeutics Inc (NASDAQ:MAZE) with a Buy rating and announced a price target of $68. Maze Therapeutics shares closed at $50.39 on Tuesday. See how other analysts view this stock.
Clear Street analyst Kaveri Pohlman initiated coverage on Evommune Inc (NYSE:EVMN) with a Buy rating and announced a price target of $53. Evommune Therapeutics shares closed at $25.03 on Tuesday. See how other analysts view this stock.
Truist Securities analyst Danielle Brill initiated coverage on Climb Bio Inc (NASDAQ:CLYM) with a Buy rating and announced a price target of $17. Climb Bio shares closed at $7.12 on Tuesday. See how other analysts view this stock.
B. Riley Securities analyst Mayank Mamtani initiated coverage on Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) with a Buy rating and announced a price target of $22. Arcturus Therapeutics shares closed at $6.39 on Tuesday. See how other analysts view this stock.
Truist Securities analyst Danielle Brill initiated coverage on Apogee Therapeutics Inc (NASDAQ:APGE) with a Hold rating and announced a price target of $83. Apogee Therapeutics shares closed at $69.85 on Tuesday. See how other analysts view this stock.

Considering buying EVMN stock? Here’s what analysts think:

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.

What's Trending

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.